Ontology highlight
ABSTRACT:
SUBMITTER: Lancet JE
PROVIDER: S-EPMC6127025 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Lancet Jeffrey E JE Uy Geoffrey L GL Cortes Jorge E JE Newell Laura F LF Lin Tara L TL Ritchie Ellen K EK Stuart Robert K RK Strickland Stephen A SA Hogge Donna D Solomon Scott R SR Stone Richard M RM Bixby Dale L DL Kolitz Jonathan E JE Schiller Gary J GJ Wieduwilt Matthew J MJ Ryan Daniel H DH Hoering Antje A Banerjee Kamalika K Chiarella Michael M Louie Arthur C AC Medeiros Bruno C BC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20180719 26
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-lab ...[more]